R-Spondin-3 antagonists (Harvard Medical School)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameR-Spondin-3 antagonists (Harvard Medical School)
Drug Alias NameRspo3 antagonists (Harvard Medical School)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionR-spondin-3 inhibitors
TargetsR-spondin-3
Therapy Area/IndicationsOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHarvard Medical School
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHarvard Medical School
Active IndicationsN/A
Inactive IndicationsOsteoporosis

Other Information

ATC CodeN/A
Related LinksN/A